Compounds > mk 0663
Page last updated: 2024-09-03

mk 0663 and 2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one

mk 0663 has been researched along with 2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one in 1 studies

Compound Research Comparison

Studies
(mk 0663)		Trials
(mk 0663)		Recent Studies (post-2010)
(mk 0663)		Studies
(2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one)		Trials
(2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one)		Recent Studies (post-2010) (2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one)
54917326547024

Protein Interaction Comparison

ProteinTaxonomymk 0663 (IC50)2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one (IC50)
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)0.3
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)0.02
Tyrosine-protein kinase JAK2Homo sapiens (human)0.1463
Tyrosine-protein kinase FynHomo sapiens (human)0.5
Tyrosine-protein kinase HCKHomo sapiens (human)7.7
Platelet-derived growth factor receptor betaHomo sapiens (human)1.49
Fibroblast growth factor receptor 1Homo sapiens (human)1.48
Platelet-derived growth factor receptor alphaHomo sapiens (human)1.49
Protein kinase C alpha typeHomo sapiens (human)1.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)1.52
Fibroblast growth factor receptor 2Homo sapiens (human)1.21
Fibroblast growth factor receptor 4Homo sapiens (human)1.48
Fibroblast growth factor receptor 3Homo sapiens (human)1.48
Tyrosine-protein kinase JAK1Homo sapiens (human)0.0865
Cyclin-dependent kinase 2Homo sapiens (human)3.3
Mitogen-activated protein kinase 3 Homo sapiens (human)1.78
Mitogen-activated protein kinase 1Homo sapiens (human)1.78
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)0.1767
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.028
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.69
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.4
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)0.16
Tyrosine-protein kinase CSKHomo sapiens (human)2.1
Tyrosine-protein kinase JAK1 Mus musculus (house mouse)0.015
Tyrosine-protein kinase JAK3Homo sapiens (human)0.0902
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.16
Maternal embryonic leucine zipper kinaseHomo sapiens (human)0.33

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boulet, L; Brideau, C; Claveau, D; Côté, B; Ducharme, Y; Ethier, D; Frenette, R; Friesen, RW; Gagnon, M; Giroux, A; Guay, J; Guiral, S; Mancini, J; Martins, E; Massé, F; Méthot, N; Riendeau, D; Rubin, J; Xu, D; Yu, H1

Other Studies

1 other study(ies) available for mk 0663 and 2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one

ArticleYear
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.
    Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24

    Topics: Analgesics, Non-Narcotic; Animals; Disease Models, Animal; Drug Design; Guinea Pigs; Humans; Hyperalgesia; Imidazoles; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Molecular Structure; Phenanthrenes; Prostaglandin-E Synthases; Rats; Structure-Activity Relationship

2007